Helix Biopharma Signs L-DOS47 Manufacturing Agreement With QSV Biologics, Ltd.

Published: Dec 22, 2005

AURORA, ON, Dec. 22 /CNW/ - Helix BioPharma Corp. (Helix; TSX, FSE: "HBP") today announced that it has signed an agreement with Edmonton, Alberta-based QSV Biologics (QSV) to develop the cGMP manufacturing process for L-DOS47. "The signing of this agreement with QSV is a major step in the L-DOS47 program," said Dr. Donald Segal, President and CEO of Helix. "We believe QSV's high caliber personnel and facilities for biopharmaceutical manufacturing will accelerate the cGMP production of L-DOS47 for our upcoming preclinical and human clinical studies."

Back to news